exogenously treated both CD4+ and CD8+ T cells, isolated from cancer specimens and found that MDA-7 in a dose-dependent manner enhanced cytolytic activity of CD8+ T cells (as monitored by target cell death and IFN-γ expression) (52). The gene discussed is CD8A; the disease is cancer.